<DOC>
	<DOC>NCT00642499</DOC>
	<brief_summary>The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients</brief_summary>
	<brief_title>Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Adherence to prior or current HAART was or is being compromised, or HAART was discontinued/interrupted due to nausea/vomiting; or beginning HAART or switching from a regimen at the time of screening for this study that did not produce significant nausea and/or vomiting to a regimen with zidovudine or a protease inhibitor (with or without low dose ritonavir). Subjects with recent (within 30 days of randomization) or current opportunistic infection or neoplasm characteristic of AIDS (Category C of the CDC Classification System for HIV1 infection, 1993 Revised Version).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>nausea</keyword>
	<keyword>vomiting</keyword>
	<keyword>HAART</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV Infections</keyword>
</DOC>